新华制药(000756) - 2016 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders was ¥43,313,070.81, reflecting a growth of 20.58% year-on-year[8]. - Operating revenue for the period was ¥977,969,739.89, representing an 18.55% increase compared to the same period last year[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥33,804,998.20, up 37.45% year-on-year[8]. - Basic earnings per share increased by 12.50% to ¥0.09[8]. - The weighted average return on equity rose by 0.31 percentage points to 2.24%[8]. - For the first nine months of 2016, total profit reached RMB 123,593,529.93, representing a 34.09% increase year-on-year, driven by product technology improvements and expanded marketing efforts[18]. - Investment income for the first nine months of 2016 was RMB 7,781,048.82, up 48.75% year-on-year, attributed to increased dividend income from available-for-sale financial assets[18]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,599,789,506.27, an increase of 2.40% compared to the end of the previous year[8]. - As of September 30, 2016, accounts receivable amounted to RMB 480,875,304.06, an increase of 52.98% compared to the beginning of the year, primarily due to the payment terms of certain sales not yet being due[17]. - The company's construction in progress as of September 30, 2016, was RMB 341,037,838.40, a significant increase of 119.56% from the beginning of the year, due to increased investment in key projects[17]. - Other current assets decreased by 65.64% to RMB 7,240,056.67, mainly due to a reduction in the value-added tax receivable[17]. - The company's long-term borrowings decreased by 73.56% to RMB 100,000,000.00, as part of the long-term debt was reclassified to current liabilities[17]. - The company reported a decrease in accounts payable by 51.98% to RMB 103,544,527.94, primarily due to the repayment of due notes[17]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥241,910,554.24, an increase of 19.62% compared to the previous year[8]. - The net cash flow from investing activities for the first nine months of 2016 was RMB -126,644,230.65, a decrease of RMB 40,638,689.82 compared to the same period last year[18]. Shareholder Information - The total number of shareholders at the end of the reporting period was 39,475[12]. - The largest shareholder, Shandong Xinhua Pharmaceutical Group Co., Ltd., holds 34.46% of the shares[12]. - The company did not engage in any repurchase transactions during the reporting period[14]. Tax and Interest Obligations - The company's interest payable increased significantly by RMB 28,980,892.72 to RMB 30,187,233.83, primarily due to interest payments on long-term borrowings at year-end[17]. - The company's tax payable increased by 37.77% to RMB 22,683,208.09, mainly due to higher value-added tax and urban construction tax obligations[17].